Lorlatinib is an antineoplastic, third-generation anaplastic lymphoma kinase (ALK)/ROS1 tyrosine kinase inhibitor that has demonstrated clinical benefit in treating advanced NSCLC, particularly in patients with central nervous system involvement or resistance to earlier ALK inhibitors [2, 3]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.